Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1996 Nov 30;313(7069):1355–1358. doi: 10.1136/bmj.313.7069.1355

Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study.

I J Jacobs 1, S Skates 1, A P Davies 1, R P Woolas 1, A Jeyerajah 1, P Weidemann 1, K Sibley 1, D H Oram 1
PMCID: PMC2352927  PMID: 8956699

Abstract

OBJECTIVE: To determine the risk of invasive epithelial ovarian cancer and fallopian tube cancer associated with a raised concentration of the tumour marker CA 125 in asymptomatic postmenopausal women. DESIGN: Serum CA 125 concentration was measured annually in study participants for one to four years. Participants with a concentration > or = 30 U/ml were recalled for abdominal ultrasonography. Follow up was by annual postal questionnaire. SETTING: General practice, occupational health departments, ovarian cancer screening unit in a teaching hospital. SUBJECTS: 22,000 volunteers, all postmenopausal women > or = 45 years of age; recruited between 1 June 1986 and 1 May 1990. INTERVENTION: Surgical investigation if the ultrasound examination was abnormal. MAIN OUTCOME MEASURES: Cumulative and relative risk of developing an index cancer (invasive epithelial cancer of the ovary or fallopian tube) after a specified CA 125 result. RESULTS: 49 index cancers developed in the study population during a mean follow up of 6.76 years. The overall cumulative risk of developing an index cancer was 0.0022 for the entire study population and was lower for women with a serum CA 125 concentration < 30 U/ml (cumulative risk 0.0012) but was appreciably increased for women with a concentration > or = 30 U/ml (0.030) and > 100 U/ml (0.149). Compared with the entire study population the relative risk of developing an index cancer within one year and five years was increased 35.9-fold (95% confidence interval 18.3 to 70.4) and 14.3-fold (8.5 to 24.3) respectively after a serum CA 125 concentration > or = 30 U/ml and 204.8-fold (79.0 to 530.7) and 74.5-fold (31.1 to 178.3) respectively after a concentration > or = 100 U/ml. CONCLUSION: CA 125 is a powerful index of risk of ovarian and fallopian tube cancer in asymptomatic postmenopausal women.

Full text

PDF
1355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bourne T. H., Campbell S., Reynolds K., Hampson J., Bhatt L., Crayford T. J., Whitehead M. I., Collins W. P. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol. 1994 Mar;52(3):379–385. doi: 10.1006/gyno.1994.1065. [DOI] [PubMed] [Google Scholar]
  3. Einhorn N., Sjövall K., Knapp R. C., Hall P., Scully R. E., Bast R. C., Jr, Zurawski V. R., Jr Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14–18. [PubMed] [Google Scholar]
  4. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  5. Helzlsouer K. J., Bush T. L., Alberg A. J., Bass K. M., Zacur H., Comstock G. W. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993 Mar 3;269(9):1123–1126. [PubMed] [Google Scholar]
  6. Jacobs I., Davies A. P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J. G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17;306(6884):1030–1034. doi: 10.1136/bmj.306.6884.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Skates S. J., Xu F. J., Yu Y. H., Sjövall K., Einhorn N., Chang Y., Bast R. C., Jr, Knapp R. C. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995 Nov 15;76(10 Suppl):2004–2010. doi: 10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  8. Woolas R. P., Xu F. J., Jacobs I. J., Yu Y. H., Daly L., Berchuck A., Soper J. T., Clarke-Pearson D. L., Oram D. H., Bast R. C., Jr Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993 Nov 3;85(21):1748–1751. doi: 10.1093/jnci/85.21.1748. [DOI] [PubMed] [Google Scholar]
  9. Woolas R., Jacobs I., Davies A. Prys, Leake J., Brown C., Grudzinskas J.G., Oram D. What is the true incidence of primary fallopian tube carcinoma? Int J Gynecol Cancer. 1994 Nov;4(6):384–388. doi: 10.1046/j.1525-1438.1994.04060384.x. [DOI] [PubMed] [Google Scholar]
  10. Zurawski V. R., Jr, Orjaseter H., Andersen A., Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988 Nov 15;42(5):677–680. doi: 10.1002/ijc.2910420507. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES